Yong-Hui Ding, Zhi-Wei Zhou, Chun-Fang Ha, Xue-Yu Zhang, Shu-Ting Pan, Zhi-Xu He, Jeffrey L Edelman, Dong Wang, Yin-Xue Yang, Xueji Zhang, Wei Duan, Tianxin Yang, Jia-Xuan Qiu, Shu-Feng Zhou
Ovarian cancer is a leading killer of women, and no cure for advanced ovarian cancer is available. Alisertib (ALS), a selective Aurora kinase A (AURKA) inhibitor, has shown potent anticancer effects, and is under clinical investigation for the treatment of advanced solid tumor and hematologic malignancies. However, the role of ALS in the treatment of ovarian cancer remains unclear. This study investigated the effects of ALS on cell growth, apoptosis, autophagy, and epithelial to mesenchymal transition (EMT), and the underlying mechanisms in human epithelial ovarian cancer SKOV3 and OVCAR4 cells...
2015: Drug Design, Development and Therapy